NCT00592488

Acetyl-L-Carnitine in the Treatment of Septic Shock

Prospective, Randomized, Placebo-controlled, Double-Blinded, Phase II Pilot Study of Acetyl-L-carnitine in the Treatment of Patients With Septic Shock

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Vanderbilt University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.

Detailed description

This is a cross-over study which infuses ALC for 12 out of 18 hours (and placebo the other 6). Patients must have vasopressor-dependent septic shock and be free from renal failure, hepatic failure, and seizures to be eligible.

Conditions

• Septic Shock

Interventions

Type	Name	Description
DRUG	Acetyl-L-Carnitine	Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours

Timeline

• Start date: 2006-08-01
• Primary completion: 2009-08-01
• Completion: 2009-09-01
• First posted: 2008-01-14
• Last updated: 2017-12-08
• Results posted: 2011-06-08

Locations

1 site across 1 country: United States